Demographics |
Patients | 538 | 3284 | |
Age years¶ | 45.1±12.5 | 43.1±13.7 | 0.001 |
Duration of disease years¶ | 12.3±10.8 | 11.6±10.9 | 0.136 |
Women | 486/538 (90) | 2326/3284 (71) | <0.001 |
Race | | | |
African American | 41/530 (8) | 667/3222 (21) | <0.001 |
White | 480/530 (91) | 2521/3222 (78) | <0.001 |
Other races+ | 10/530 (2) | 74/3222 (2) | 0.55 |
Healthcare insurance |
Private health insurance | 332/531 (62.5) | 1816/3256 (56) | 0.004 |
Government insurance | 211/531 (40) | 1078/3256 (33) | 0.003 |
No health insurance | 55/531 (10) | 621/3256 (19) | <0.001 |
Graduated college or university | 284/473 (60) | 1394/2594 (54) | 0.01 |
Income USD | | | 0.50 |
<35000 | 127/442 (29) | 656/2513 (26) | |
35000–99999 | 197/442 (44.5) | 1173/2513 (47) | |
>100000 | 118/442 (26.5) | 684/2513 (27) | |
Healthcare providers seen before sarcoidosis diagnosis was made§ |
Endocrinologist | 115/538 (21) | 241/3284 (7) | <0.001 |
Primary care provider | 436/538 (81) | 2623/3284 (80) | 0.53 |
Other specialists | 451/538 (83) | 2569/3284 (78) | 0.003 |
Family history of sarcoidosis | 81/446 (18) | 476/2707 (18) | 0.77 |
Ever admitted to hospital in relation to sarcoidosis | 185/498 (37) | 1158/2995 (39) | 0.52 |
Sarcoidosis-specific therapyƒ |
Steroids | 416/536 (78) | 2356/3262 (72) | 0.009 |
Cytotoxic agents | 254/382 (66.5) | 1339/2076 (64.5) | 0.45 |
Tumour necrosis factor inhibitors | 79/312 (25) | 376/1712 (22) | 0.19 |
Others | 38/291 (13) | 142/1616 (9) | 0.007 |